| |
Learn how raw materials affect process consistency and ATMPs, the essential components of a GMP framework, strategies to find a trusted vendor including an evaluation checklist, and more. Read Now >> 
|
|
Today’s Big NewsDec 3, 2024 |
| By Fraiser Kansteiner Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission to the fore with a new deal featuring Swiss drug juggernaut Roche. |
|
|
|
By Darren Incorvaia Gilead is making a move in the hunt for antibody-drug conjugates (ADCs) that target solid tumors by tapping Tubulis, a German biotech that specializes in the molecules, to collaboratively discover and develop a topoisomerase I inhibitor-based ADC candidate. |
By Kevin Dunleavy Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven platform to discover and develop therapeutic miniproteins for two undisclosed targets. |
By Nick Paul Taylor Takeda is paying Keros Therapeutics $200 million upfront to bolster its late-stage cancer pipeline. The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with Bristol Myers Squibb’s Reblozyl in blood cancer indications. |
By Nick Paul Taylor Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French drugmaker exclusive global rights to a preclinical Biomunex Pharmaceuticals prospect that engages a subset of cytotoxic T cells. |
By Gabrielle Masson Kinevant Sciences, a Roivant spinout designed to test an investigational monoclonal antibody, has reported that the asset failed to help patients with an inflammatory lung disease in a midstage trial. |
By Zoey Becker The latest dataset for Janux' JANX007 showed that all 16 patients with heavily pre-treated metastatic prostate cancer achieved a 50% decline in prostate-specific antigens. The result sent the biotech's shares soaring nearly 60%. |
By Kevin Dunleavy As part of its second reorganization in 16 months, Agenus will offer CDMO services at its two manufacturing sites in California, performing production of biologics products for clients. |
By Heather Landi Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out drug discounts to hospitals. |
By Conor Hale GE HealthCare plans to take full control of Nihon Medi-Physics, maker of diagnostic radiopharmaceuticals and molecular imaging agents. The company had previously split ownership of the Tokyo-based nuclear medicine outfit down the middle with Sumitomo Chemical. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
